Decision curve analysis (DCA) is a method for evaluating the benefits of a diagnostic test across a range of patient preferences for accepting risk of undertreatment and overtreatment to facilitate decisions about test selection and use.1 In this issue of JAMA, Siddiqui and colleagues2 used DCA to evaluate 3 prostate biopsy strategies: targeted magnetic resonance/ultrasound fusion biopsy, standard extended-sextant biopsy, or a combination, for establishing the diagnosis of intermediate- to high-risk prostate cancer. Their goal was to identify the best biopsy strategy to ensure prostatectomy is offered to patients with intermediate- and high-risk tumors and avoided for patients with low-risk tumors.
Fitzgerald M, Saville BR, Lewis RJ. Decision Curve Analysis. JAMA. 2015;313(4):409-410. doi:10.1001/jama.2015.37